Saturday, November 05, 2016 10:50:05 AM
However, once an estimate is made, the calculation for the value in dollars per share is relatively simple as I discussed. Remember a "buyout" would include all outstanding shares as well as all outstanding warrants, stock options and debt. So even though there are only 86M shares of PTN currently outstanding, one must try to figure out the total share count when fully diluted after conversion of warrants, stock options, etc. to common shares. I estimated 200M shares for this number, but should be able to update this once their next 10-Q report is released.
The real unknown here is timing of a buyout announcement. Some have guessed by end of November, others by end of 2016. Still others have guessed several months to as long as 6 months. Normally I would guess 3-6 months also. However in this case, there are 3 reasons why I suspect a deal could be announced within 1-2 months:
1) PTN is nearly out of cash as we will see in their next 10-Q report. So unless they plan to raise more cash by issuing more shares (like they did recently), they will need to make a deal ASAP.
2) Also, since PTN has probably known about the positive trial outcome for many months, they have already had time to put out feelers for a buyout and probably also had time to do some "preliminary" negotiations with 1 or more potential buyers.
3) There is a rumor that has been reported that PTN has retained a vendor to handle negotiating the best possible deal for them. That could be a buyout or some other arranged takeover (merger, partnership, etc.)
Disclaimer: All of the above are my own opinions. No one should buy or sell shares of PTN based on these opinions. As always, DO YOUR OWN DD!
Recent PTN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 02:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 02:00:32 PM
- Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results • PR Newswire (US) • 11/14/2024 12:30:00 PM
- Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 • PR Newswire (US) • 11/08/2024 02:57:00 PM
- Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 • PR Newswire (US) • 11/04/2024 12:30:00 PM
- Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity • PR Newswire (US) • 10/31/2024 11:30:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/30/2024 01:07:01 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/30/2024 04:15:05 AM
- Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium • PR Newswire (US) • 10/24/2024 11:30:00 AM
- Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium • PR Newswire (US) • 10/23/2024 11:30:00 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/22/2024 08:31:17 PM
- Palatin Receives Notice of Non-Compliance from NYSE American • PR Newswire (US) • 10/07/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 12:15:23 PM
- Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones • PR Newswire (US) • 10/01/2024 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/30/2024 08:31:04 PM
- Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results • PR Newswire (US) • 09/26/2024 11:30:00 AM
- Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones • PR Newswire (US) • 09/09/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:35:29 PM
- FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) • PR Newswire (US) • 08/28/2024 11:30:00 AM
- First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity • PR Newswire (US) • 08/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:01:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:31:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:31:01 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/25/2024 08:46:11 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM